As a wholly-owned subsidiary of Loncompharma CO., Ltd., the company was founded in May 2018. The company is located in Osaka.

There are currently 13 production lines for solid oral preparations, oral liquid preparations, and API, based on the API pilot test, production base, and formulation production base that the company constructed according to European, American, and international standards. A focus is placed on formulation workshops for small-volume injections, soft capsules, eye drops, topical medicines, and innovative drug research and development centres. Eventually, Loncompharma Co., Ltd will become a modern high-tech pharmaceutical company that integrates R&D, production, and marketing of new pharmaceutical products.